Remix Therapeutics

Remix Therapeutics™ to Present at 46th Annual Canaccord Genuity Growth Conference

Watertown, Mass., August 4, 2026 – Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of…

Download the latest corporate deck

Remix-Corporate-Presentation-July-2026 The post Download the latest corporate deck appeared first on Remix Therapeutics .

Remix Therapeutics™ to Present at AACR Drug Discovery and Development Conference

Presentation to Highlight Phase 1 REM-422 ACC Data Demonstrating 43% Overall Response Rate and Durable Responses Exceeding One Year with Favorable Safety Results   Watertown, Mass., July 16, 2026 – Remix Therapeutics (Remix), Inc., a clinical-stage biotechnology company developing small molecule…

Passage Bio and Remix Therapeutics™ Announce Merger Agreement

Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin Remix’s lead program, REM-422, is an orally available mRNA degrader targeting MYB, a historically…

Remix Therapeutics™ Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical Oncology Annual Meeting 2026

Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a Favorable Safety Profile Anti-Tumor Activity Seen Across ACC Subtypes and Regardless of Prior Lines of Therapy 100% Disease Control Rate with Patients…

Remix Therapeutics™ Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting

Results of Phase 1 Dose-Escalation Cohort Including Antitumor Activity and Safety of REM-422 in Adenoid Cystic Carcinoma   Watertown, Mass., April 21, 2026 – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address…